Sulpiride

NERVOUS SYSTEM

Key facts

Sulpiride is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1972. DrugCentral lists 31 molecular targets, including CA6, Drd2 and CA7. Recorded indications include Schizophrenia.

• Molecular targets: CA6, Drd2, CA7 and CA12 (31 listed in DrugCentral).
• Indications: Schizophrenia.
• ATC code: N05AL01 (Benzamides).
• Molecular formula: C15H23N3O4S; molecular weight 341.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Schizophrenia

Mechanism & targets

Molecular targets (31)

Target	Gene	Action	Activity
Carbonic anhydrase 6	CA6	unknown	Ki 9.10
D(2) dopamine receptor	Drd2	unknown	Kd 8.82
Carbonic anhydrase 7	CA7	unknown	Ki 8.44
Carbonic anhydrase 12	CA12	unknown	Ki 8.41
D(2) dopamine receptor	DRD2	antagonist	Ki 8.12
D(3) dopamine receptor	DRD3	unknown	Ki 8.10
Carbonic anhydrase 5B, mitochondrial	CA5B	unknown	Ki 7.74
Carbonic anhydrase	—	unknown	Ki 7.53
Carbonic anhydrase 9	CA9	unknown	Ki 7.51
Carbonic anhydrase	NCE103	unknown	Ki 7.40
Carbonic anhydrase 2	CA2	unknown	IC50 7.40
Carbonate dehydratase	—	unknown	Ki 7.17
Carbonic anhydrase 15	Ca15	unknown	Ki 7.14
Carbonic anhydrase	—	unknown	Ki 6.95
Carbonic anhydrase	NCE103	unknown	Ki 6.91
Carbonic anhydrase 5A, mitochondrial	CA5A	unknown	Ki 6.76
Carbonic anhydrase	cynT	unknown	Ki 6.75
D(2) dopamine receptor	DRD2	unknown	IC50 6.70
Delta carbonic anhydrase	ca1	unknown	Ki 6.59
Carbonic anhydrase 2	mtcA2	unknown	Ki 6.58

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1972-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
N05AL01	NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Benzamides

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Suicide attempt	202.7
Electrocardiogram QT prolonged	169.6
Parkinsonism	134.7
Torsade de pointes	115.6
Extrapyramidal disorder	107.6
Toxicity to various agents	96.3
Neuroleptic malignant syndrome	73.3
Psychomotor retardation	71.8
Intentional overdose	71.2
Fall	69.7
Somnolence	68.5
Cerebellar syndrome	62.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sulpiride is on its molecule page.

• Molecular formula: C₁₅H₂₃N₃O₄S
• Molecular weight: 341.43 g/mol
• CAS number: 15676-16-1
• InChIKey: BGRJTUBHPOOWDU-UHFFFAOYSA-N
• PubChem CID: 5355

CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulpiride used for?

DrugCentral lists the following indications for Sulpiride: Schizophrenia.

How does Sulpiride work?

Its molecular targets in DrugCentral include CA6, Drd2, CA7 and CA12.

When was Sulpiride first approved?

Sulpiride was first approved by the YEAR INTRODUCED in 1972.

What is the chemical formula of Sulpiride?

Sulpiride has the molecular formula C15H23N3O4S and a molecular weight of 341.43 g/mol.

Sources

• DrugCentral drug card 2537 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL26 — compound record and bioactivity
• PubChem CID 5355 — chemical identifiers
• DrugBank DB00391 — drug record
• FDA UNII 7MNE9M8287 — substance identity
• UniProt P23280 (CA6) — target protein
• UniProt P43166 (CA7) — target protein
• UniProt O43570 (CA12) — target protein
• UniProt P14416 (DRD2) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt Q9Y2D0 (CA5B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.